参考文献/References:
[1] Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma[J]. Gastroenterology, 2004, 127: S179-S188.
[2] Melero I, Berman DM, Aznar MA, et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer[J]. Nat Rev Cancer, 2015, 15: 457-472.
[3] Li S, Yang F, Ren X. Immunotherapy for hepatocellular carcinoma[J]. Drug Discov Ther, 2015, 9: 363-371.
[4] Matar P, Alaniz L, Rozados V, et al. Immunotherapy for liver tumors: present status and future prospects[J]. J Biomed Sci, 2009, 16: 30.
[5] Greten TF, Wang XW, Korangy F. Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches[J]. Gut, 2015, 64: 842-848.
[6] Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12: 252-264.
[7] Yao S, Chen L. PD-1 as an immune modulatory receptor[J]. Cancer J, 2014, 20: 262-264.
[8] Okazaki T, Chikuma S, Iwai Y, et al. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application[J]. Nat Immunol, 2013, 14: 1212-1218.
[9] Gao Q, Wang XY, Qiu SJ, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma[J]. Clin Cancer Res, 2009, 15: 971-979.
[10] El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma （CheckMate 040）: an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389: 2492-2502.
[11] European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69: 182-236.
[12] Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib （KEYNOTE-224）: a non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19: 940-952.
[13] Wainberg ZA, Segal NH, Jaeger D, et al. Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma （HCC）[J]. J Clin Oncol, 2017, 35: 4071.
[14] Hickey RM, Kulik LM, Nimeiri H, et al. Immuno-oncology and its opportunities for interventional radiologists: immune checkpoint inhibition and potential synergies with interventional oncology procedures[J]. J Vasc Interv Radiol, 2017, 28: 1487-1494.
[15] Liao J, Xiao J, Zhou Y, et al. Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinoma[J]. Mol Med Rep, 2015, 12: 6065-6071.
[16] 韩聚强， 范公忍， 任永强，等. 不同微创介入治疗原发性肝癌对机体T细胞免疫功能的影响[J]. 介入放射学杂志， 2014， 23：218-221.
[17] 李虎子， 郭?志， 王海涛， 等. 肝细胞癌患者TACE后外周血调节性T细胞水平对预后的影响[J]. 介入放射学杂志， 2012， 21：998-1001.
[18] 王立静， 苗同国， 宁更献， 等. 肝动脉化疗栓塞术对原发性肝癌患者T淋巴细胞亚群的影响[J]. 介入放射学杂志， 2015， 24：165-168.
[19] Xue TC, Jia QA, Ge NL, et al. Imbalance in systemic inflammation and immune response following transarterial chemoembolization potentially increases metastatic risk in huge hepatocellular carcinoma[J]. Tumour Biol, 2015, 36: 8797-8803.
[20] 卢?伟， 李彦豪， 何晓峰， 等. 经导管动脉化疗栓塞术中化疗药物剂量对肝癌患者T细胞亚群的影响[J]. 第一军医大学学报， 2002， 22：524-526.
[21] Heianna J, Miyauchi T, Suzuki T, et al. Spontaneous regression of multiple lung metastases following regression of hepatocellular carcinoma after transcatheter arterialembolization. A case report[J].Hepatogastroenterology, 2007, 54: 1560-1562.
[22] Ayaru L1, Pereira SP, Alisa A, et al. Unmasking of alpha-fetoprotein-specific CD4+T cell responses in hepatocellular carcinoma patients undergoing embolization[J]. J Immunol, 2007, 178: 1914-1922.
[23] Takaki H, Imai N, Contessa TT, et al. Peripheral blood regulatory T-cell and type 1 helper T-cell population decrease after hepatic artery embolization[J]. J Vasc Interv Radiol, 2016, 27: 1561-1568.
[24] Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia[J]. Cancer Cell, 2014, 26: 605-622.
[25] Noman MZ, Desantis G, Janji B, et al. PD-L1 is a novel direct target of HIF-1 alpha., and its blockade under hypoxia enhanced MDSC-mediated T cell activation[J]. J Exp Med, 2014, 211: 781-790.
[26] Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2017, 66: 545-551.
[27] Mocan T, Sparchez Z, Craciun R, et al. Programmed cell death protein-1（PD-1）/programmed death-ligand-1（PD-L1） axis in hepatocellular carcinoma: prognostic and therapeutic perspectives[J]. Clin Transl Oncol, 2019, 21: 702-712.